This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will UnitedHealth (UNH) Q1 Earnings Buoy on Revenue Growth?
by Zacks Equity Research
UnitedHealth's (UNH) Q1 earnings should see an upside from revenue growth at both its segments - Optum and UnitedHealthcare.
Molina Healthcare (MOH) Tops on Q4 Earnings, Issues '18 View
by Zacks Equity Research
Restructuring costs and impairment loss affect Molina Healthcare's (MOH) fourth-quarter results.
4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now
by Zacks Equity Research
Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.
PerkinElmer Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
PerkinElmer's (PKI) shares hit a new 52-week high on the back of broad product spectrum and acquisition-led growth.
CVS Health Grows on Pharmacy Services, Retail Remains a Drag
by Zacks Equity Research
CVS Health's (CVS) strong Pharmacy Services business continues to gain from a sturdy Specialty Pharmacy. However, its highly competitive retail pharmacy business raises concern.
Boston Scientific's Positive SCS Trial Aids Neuromodulation
by Zacks Equity Research
Boston Scientific's (BSX) WHISPER RCT data demonstrates that sub-perception and paresthesia-based SCS therapies deliver superior results when applied as a combo regimen.
IDEXX Launches Catalyst SDMA for Veterinary Renal Disorder
by Zacks Equity Research
IDEXX Laboratories (IDXX) already puts its Catalyst SDMA Test to use for hundreds of medical practices across the United States.
Boston Scientific Fortifies Pain Therapy Arm With FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) claims its Spectra WaveWriter Spinal Cord Stimulator System to combine both paresthesia-based and sub-perception therapies to target a specific area of pain.
5 HMO Stocks to Continue Rewarding Investors
by Sejuti Banerjea
Here are five Buy-rated HMO stocks that should be in your portfolio.
Abaxis' Product Line Expansion Aids Growth, Rivalry Rife
by Zacks Equity Research
Abaxis' (ABAX) growing portfolio of rapid test menu and a strong performance in Veterinary consumables drive growth. Intense competition in both the Medical and Veterinary markets is a concern.
Stryker (SYK) Posts Upbeat Preliminary Sales Figure for Q4
by Zacks Equity Research
Stryker Corporation's (SYK) fourth quarter and 2017 preliminary net sales figures are encouraging, courtesy of balanced revenue growth in all business segments.
Teladoc Provides Strong Preliminary Results & 2018 Outlook
by Zacks Equity Research
Teladoc's (TDOC) impressive fourth-quarter preliminary results and 2018 guidance reflects the company's solid business growth.
Will Tenet Healthcare Gain from Tax Refrom & Growth Measures?
by Zacks Equity Research
Tenet Healthcare (THC) to feel the pinch of tax reform before enjoying its benefits; growth strategies on track.
Ensign Group (ENSG) Grows on Buyouts, High Debt Level a Drag
by Zacks Equity Research
Growing top line, solid inorganic strategies and healthy balance sheet position Ensign Group (ENSG) for long-term growth. However, rising level of debt and expenses hurt the bottom line.
The Zacks Analyst Blog Highlights: Anthem, Humana, Centene, Molina Healthcare and Joint
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthem, Humana, Centene, Molina Healthcare and Joint
3 Outperformers from Health Insurance in 2017
by Zacks Equity Research
The health insurance industry has witnessed regulatory uncertainties around Affordable Care Act, public exchange losses and inorganic growth in 2017.
Molina Healthcare (MOH) Jumps: Stock Rises 14.8%
by Zacks Equity Research
Molina Healthcare (MOH) shares rose nearly 15% in the last trading session, amid huge volumes.
Molina Healthcare (MOH) Q3 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Molina Healthcare's (MOH) third-quarter earnings were driven by solid revenue growth.
Health Care Stocks Stumble on Trump's Executive Order
by Zacks Equity Research
Trump's executive order has sent jitters across the hospital sector that has been weighed down by a weak business environment also insurers remain unsure.
Molina Healthcare Appoints CEO: Will New Leadership Help?
by Zacks Equity Research
Molina Healthcare (MOH) appoints new CEO in an attempt to regain its lost glory.
How Molina Healthcare (MOH) Stock Stands Out in a Strong Industry?
by Zacks Equity Research
Molina Healthcare (MOH) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective
Health Care Stocks in Focus as Repeal & Replace Gains Steam
by Zacks Equity Research
Healthcare stocks are jittery due to the regulatory uncertainty that the Graham-Cassidy bill may bring along.
Molina Healthcare (MOH) Up 5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Molina Healthcare (MOH) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Molina Healthcare's Top Line Grows on Membership, Debts Hurt
by Zacks Equity Research
Molina Healthcare's (MOH) top line benefits from inorganic growth and membership. However, rising level of debt and expenses hurt margins.
Molina Healthcare (MOH) Incurs Loss in Q2, Revenues Beat
by Zacks Equity Research
Molina Healthcare (MOH) incurred loss in the second-quarter 2017 owing to higher medical care costs.